Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema
ConclusionsIntravitreal ranibizumab was helpful for either vitrectomized or non-vitrectomized eyes with DME in short-term follow-up. Anatomical and functional improvements were greater in non-vitrectomized patients than in vitrectomized cases.
Source: International Ophthalmology - Category: Opthalmology Source Type: research
More News: Diabetes | Endocrinology | Eyes | Lucentis | Opthalmology | Ranibizumab Injection | Study